A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Study of trastuzumab emtansine (T-DM1) administered to patients with human epidermal growth
factor receptor 2 (HER2)-positive metastatic breast cancer.